NSE ScannerFertilisers & Agrochemicals · Chemicals: Agricultural · NSE: ASTEC · data 2026-10-30
Astec Lifesciences Limited
In plain words
Price: 42.1% below its 52-week high of ₹941.75.
Delivery: 37.2% of traded shares were kept for delivery over the last 10 sessions, against 38.8% over the last 60.
Latest results: a net loss of ₹37 cr for the quarter ended Sept 2026.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹439 cr |
| Net profit (last 12 months) | ₹-80 cr |
| Sales growth, 3 years (yearly) | -10.7% |
| Profit growth, 3 years (yearly) | — |
Latest results in brief (Q2 FY27)
ASTEC Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹72.02 crore, down 2.3% YoY and down 13.8% QoQ.
Net loss was ₹37.41 crore, a bigger loss than a year ago and a bigger loss than last quarter.
Operating margin was 27.5% (9.1% a year ago).
EPS was -₹16.79, more negative than a year ago and more negative than last quarter.
ASTEC के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹72.02 करोड़; पिछले साल की तुलना में 2.3% की गिरावट, पिछली तिमाही की तुलना में 13.8% की गिरावट।
शुद्ध घाटा: ₹37.41 करोड़; एक साल पहले से घाटा बढ़ा, पिछली तिमाही से घाटा बढ़ा।
ऑपरेटिंग मार्जिन: 27.5% (एक साल पहले 9.1%)।
EPS: -₹16.79; एक साल पहले से अधिक ऋणात्मक, पिछली तिमाही से अधिक ऋणात्मक।
ASTECના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹72.02 કરોડ; ગયા વર્ષની સરખામણીએ 2.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 13.8% ઘટાડો.
ચોખ્ખી ખોટ: ₹37.41 કરોડ; એક વર્ષ પહેલાંની સરખામણીએ ખોટ વધી, ગયા ક્વાર્ટરની સરખામણીએ ખોટ વધી.
ઓપરેટિંગ માર્જિન: 27.5% (એક વર્ષ પહેલાં 9.1%).
EPS: -₹16.79; એક વર્ષ પહેલાંના કરતાં વધુ નકારાત્મક, ગયા ક્વાર્ટરના કરતાં વધુ નકારાત્મક.
Written from the filed numbers. Not a recommendation.
Smart-money activity
19/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 14/30: Delivery 28.9% over the last 20 sessions vs 11.3% in the 40 before (2.56x); shares delivered per day 0.53x usual; 1 delivery-spike day (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Rights
- 26 Oct 26Results Q2 FY27 results: loss widened vs a year ago -3.0% next session
- 31 Jul 26Results Q1 FY27 results: loss narrowed vs a year ago +0.2% next session
- 27 Apr 26Results Q4 FY26 results: loss narrowed vs a year ago +0.8% next session
- 30 Jan 26Results Q3 FY26 results: loss narrowed vs a year ago -1.0% next session
- 29 Oct 25Results Q2 FY26 results: loss narrowed vs a year ago -3.3% next session
- 28 Jul 25Results Q1 FY26 results: loss narrowed vs a year ago -3.0% next session
- 4 Jul 25Rights Rights issue 1:7 · premium ₹880 (ex-date) -1.5% next session
- 9 May 25Results Q4 FY25 results: loss widened vs a year ago +3.4% next session
- 27 Jan 25Results Q3 FY25 results: loss widened vs a year ago +1.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹72 cr | ₹-37 cr | — | -27.5% | -16.79 |
| Jun 2026 | ₹84 cr | ₹-19 cr | — | -0.8% | -8.4 |
| Mar 2026 | ₹159 cr | ₹-8 cr | — | 5.8% | -3.48 |
| Dec 2025 | ₹125 cr | ₹-16 cr | — | 3.2% | -7.04 |
Common questions
What was Astec Lifesciences Limited's latest quarterly profit?
Astec Lifesciences Limited reported a net loss of ₹37 cr for the quarter ended Sept 2026, on revenue of ₹72 cr.
Is Astec Lifesciences Limited debt-free?
Its latest reported debt-to-equity ratio is 1.15, meaning borrowings are larger than shareholders' equity.
What is the 52-week high and low of Astec Lifesciences Limited?
The 52-week high is ₹941.75 and the 52-week low is ₹513.4.
Similar companies
India Pesticides Ltd. (IPL) · Punjab Chemicals & Crop Protection Ltd. (PUNJABCHEM) · Kothari Industrial Corp. Ltd. (KOTIC) · 3B BlackBio Dx Ltd (3BBLACKBIO) · Southern Petrochemical Industries Corporation Limited (SPIC)
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ASTEC in NSE Scanner →